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ABSTRACT
Wipf, Israel. Investigating the Role of ATP-Binding Cassette Transporters in Drosophila
melanogaster Testis Stem Cells. Unpublished Master of Science thesis, University of
Northern Colorado, 2021.

Multidrug resistance is among the most pressing obstacles in cancer treatment today.
Resistance is thought to arise from the ability of cancer stem cells to efflux therapeutic molecules
using a collection of membrane proteins called ATP-binding cassette (ABC) transporters. There
is strong interest in targeting ABC transporters to preserve and improve drug efficacy and reduce
cancer recurrence. Many studies have been performed in vitro using cultured cell lines, but
currently there is a lack of simple models in which to study ABC transporters in vivo. As a
solution, I propose to use the fruit fly Drosophila melanogaster for the study of ABC
transporters, and specifically the D. melanogaster testis stem cell niche—one of the bestcharacterized adult stem cell niches. Stem cells have several traits in common with cancer cells,
including the ability to divide indefinitely, the ability to give rise to many different kinds of
daughter cells, and chemoresistance. In invertebrates there is mounting evidence for a role ABC
transporters play in insecticide resistance, but to date there is no peer-reviewed evidence for
invertebrate stem cell drug resistance in the literature. Here, I present evidence of cytotoxic drug
efflux in the germline stem cells of the D. melanogaster testis. This was accomplished by
feeding the chemotherapy drug doxorubicin to wild type flies for two days and measuring
fluorescence levels using confocal microscopy. Using enhancer trap lines, I also present ABC
transporter expression evidence in both the germline and cyst lineages of the testis. Finally,
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through RNAi knockdown of several ABC transporters, I present evidence of their contribution
to germline stem cell drug efflux. I also report unexpected phenotypes in the male germline
resulting from the knockdown of two ABC transporters, CG32901 and CG3164, which points to
a role for these proteins in development of the normal testes niche.
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CHAPTER I
INTRODUCTION
ATP-Binding Cassette Transporters, Multidrug Resistance,
and Cancer Stem Cells
One of the most pressing obstacles in cancer treatment is the resistance of cancer stem
cells to conventional chemotherapy drugs [1-4]. In many instances, drugs may eradicate the
majority of a tumor mass but leave behind the cancer stem cells, ultimately leading to cancer
recurrence. Multidrug resistance is thought to arise from the ability of cancer stem cells to efflux
therapeutic molecules using a collection of transmembrane proteins called ATP-binding cassette
(ABC) transporters. This family of proteins has been implicated not only in cancer drug
resistance [5], but also in cystic fibrosis [6, 7], and antibiotic resistance [8, 9]. Collectively, the
ABC transporter family are capable of transporting an extremely wide variety of substrates—
from small inorganic ions to both drugs and polypeptides. The family is divided into seven
classes or subfamilies (ABCA - ABCG) based on amino acid sequence similarities, but so far
only subfamilies A, B, C, and G have been implicated in cancer multidrug resistance [10]. The
unifying feature of all ABC transporters is that they consist of two distinct protein domains: a
transmembrane domain (TMD) embedded within the cell membrane, and a cytosolic nucleotide
binding domain (NBD) which binds and hydrolyzes adenosine triphosphate (ATP) to fuel
substrate transport. Structurally, ABC transporters exist as either full transporters, usually
containing two TMD and two NBD each, or half transporters with only one TMD and NBD,
which must form homo- or heterodimers to function [11]. While the ABC transporter family as a
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whole is collectively capable of transporting a wide variety of substrates, most individual ABC
transporters are specific for one or a few substrates. Such specificity is determined by the
structure of their TMD. Many ABC transporters have overlapping substrate specificity [12],
while the specific substrates and functional roles of many ABC transporters remain unknown.
Cancer multidrug resistance (MDR) is a phenomenon which occurs when cancer cells
simultaneously become resistant to a host of structurally and functionally unrelated drugs. MDR
has been observed in a number of different cancers, including acute myelogenous leukemia
(AML), sarcomas, and breast, ovarian, and lung cancer [13-15]. There are a number of cellular
mechanisms by which MDR can arise, such as blocking apoptotic pathways or activating DNA
repair pathways (Figure 1.1), but the mechanism most often encountered is increased efflux by
ABC transporters [13]. The contribution of ABC transporters to the development of MDR in
cancer cells has been known for some time. ABCB1 (also known as P-glycoprotein or MDR1),
first discovered in 1976, was shown to be expressed in drug-resistant mutants of the Chinese
hamster ovary, or the CHO cell line [16]. Subsequently, numerous ABCB1 small-molecule
inhibitors were developed in hopes of treating MDR, but not a single one of them became an
enduring treatment option for patients [17]. Three generations of ABCB1 small-molecule
inhibitors were tested in dozens of clinical studies throughout the 1980s and 1990s. While there
were some apparent early successes (such as verapamil to treat lymphoma) [18], these inhibitors
ultimately failed to prove safe and effective [15, 19]. These and subsequent disappointments led
to outspoken pessimism regarding the pursuit of future ABC transporter inhibitors [20, 21], and
ultimately the suppression of further research in this area for some decades [22]. In hindsight, it
appears that the failure of those early clinical trials was due, at least in part, to their narrow focus
on just one of the 48 distinct human ABC transporters, ABCB1, as a therapeutic target. This is
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obviously problematic, because we now understand that many distinct ABC transporters may be
expressed simultaneously within a single tumor. Today, at least 12 human ABC transporters
from four subfamilies (ABC-A, ABC-B, ABC-C, and ABC-G) have been implicated in cancer
MDR, and studies using cultured cancer cell lines have revealed that two proteins other than
ABCB1 are predominantly responsible for MDR, ABCC1 and ABCG2, neither of which was a
target in those early clinical trials [13]. Another issue was the lack of appropriate tools, such as
methods for accurately detecting ABCB1 expression in human cancers (let alone other ABC
transporters) [15], as well as robust tools for studying gene expression and mutation in general
[14].

Figure 1.1: Cellular mechanisms of multidrug resistance, including increased efflux activity
conferred by ABC transporters. Borrowed from Gottesman et al., 2002. [15]

Today there is renewed interest in developing ways to target ABC transporters, and a
growing body of evidence suggests that such efforts could make both classical chemotherapy
drugs and small-molecule inhibitors more effective and reduce the rate of cancer recurrence [3,
4, 22-25]. Currently, however, there is a lack of simple models in which to study ABC
transporters in vivo. Many of the today’s investigations into cancer stem cell drug resistance are
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being performed in vitro using cultured cell lines [23, 26]. While these kinds of experiments
have proven useful in identifying some resistance-thwarting drugs [27, 28], they are limited in
their ability to account for the influence of a particular tissue’s microenvironment. Not only are
cancer cells exposed to various cytokines and growth factors from the surrounding tissue, but
solid tumors often have areas which are hypoxic, nutrient-deprived, and highly acidified [5].
Indeed, hypoxia is even thought to be a biomarker for resistant cancer cells [29]. As such, in
vitro models that do not take the physiology of these microenvironments into account are
missing potentially valuable insights [30].
A solution to this problem may lie in the idea that chemoresistance is not exclusive to
cancer cells but appears to be a general stem cell trait. Not all stem cells exhibit chemoresistance
through elevated efflux activity. Those that do have come to be referred to as “side population”
cells, first identified by their ability to exclude Hoechst 33342, a blue, fluorescent dye which
binds to AT-rich regions of DNA [31]. Side population cells have since been identified in a
variety of tissues (e.g. skin, heart, brain) [32]. Some cancer cells also exhibit this elevated efflux
ability, and these cells are thought to be capable of both tumor initiation and repopulation [33].
In other words, these cells seem to function as cancer stem cells (CSCs). The theory of CSCs is
now well established in the scientific community [1-4], and there is growing interest in targeting
CSCs to potentially increase the efficacy of anti-tumor therapies (Figure 1.2). Furthermore, there
is accumulating evidence that both ABC transporter expression and elevated efflux might be
general stem cell properties, shared by both CSCs and normal stem cell populations alike [34].
(Also see Appendix A for evidence of dye exclusion in normal stem cells). This finding makes
sense conceptually, as it would be important for stem cells to have a defense mechanism against
harmful toxins in order to repopulate their respective tissues. Interestingly, it also suggests that
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ABC transporter overexpression might be an evolved stem cell defense mechanism that has been
hijacked for cancer chemoresistance. Given this, it is quite possible that well-established stem
cell model systems could be used to shed new light on the workings of ABC transporters and
their role in cancer MDR.

Figure 1.2: The theory of cancer stem cells posits that some cancer cells have stem-like
properties enabling them of tumor initiation and repopulation. Targeting cancer stem cells could
increase the efficacy of chemotherapies and reduce tumor recurrence. Borrowed from Reya et
al., 2001. [3]

ATP-Binding Cassette Transporter Expression:
A General Stem Cell Trait
The finding that ABC transporters are expressed within some normal stem cell
populations may present the opportunity to study proteins important to cancer MDR using wellestablished in vivo stem cell models. The fate of any stem cell daughter is either renewal of the
stem cell state or differentiation into a cell type specific to the tissue in which the stem cell
resides. That is, stem cells daughters either self-renew or differentiate. When germline stem cells
divide, for example, their progeny either retain the stem cell state or begin to develop into mature
germ cells, ultimately giving rise to gametes. To make this fateful decision, the stem cell depends
on signals from its local microenvironment, or niche [35]. These signals might come from nearby
somatic cells or other stem cells. There is evidence that these local signals suppress
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differentiation, and that distance away from the niche and its signals allows for differentiation
[36]. As local signals appear to be instrumental to maintaining the stem cell state, it makes sense
to study stem cell properties such as efflux ability in the context of these signals, and not isolated
from them. One of the obstacles to doing so, however, is the complexity of stem cell niches and
the difficulty of genetic manipulations in mammals. Such complexity makes it difficult to
identify and genetically manipulate specific cell populations [37], as well as difficult to elucidate
the precise signaling interactions between cell populations in the niche [38, 39]. Such difficulties
could be overcome by employing a simpler model organism, such as Drosophila melanogaster.
The benefits of using D. melanogaster are numerous. They include a short generation
time, inexpensive maintenance, and a well-developed catalogue of robust genetic tools such as
the Gal4-UAS system [40-42]. The breadth of both Gal4 lines and UAS reporter lines available
make this a powerful system for manipulating and studying gene expression in vivo. Moreover, it
is thought that ~ 65% of disease-causing genes in humans have fly homologs [43], giving them
significant relevance to biomedical research. One area of research this organism is especially
well-suited for is stem cell biology. In particular, the D. melanogaster testis stem cell niche
(Figure 1.3), with its ease of manipulation and imaging and its well-characterized tissue
architecture, is among the best models for studying adult stem cells in vivo [37, 44]. This niche
supports two distinct populations of stem cells—germline stem cells and cyst stem cells—both of
which cluster around a small group of somatic, nondividing cells called the hub. This clustering
allows the stem cells to be identified by their position within the testis, as the stem cells are
always found adjacent to the hub, and thus stem cell-specific stains are not necessary for
identification. Furthermore, stem cells have several traits in common with cancer, including the
ability to divide indefinitely, the ability to give rise to different kinds of daughter cells in some
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cases, and chemoresistance, often through ABC transporter expression and elevated efflux
activity. Given the similarities between stem cells and cancer, the D. melanogaster testis stem
cell niche could, in theory, serve as a useful tool for the study of ABC transporters in vivo.

Figure 1.3: Conceptual model of the Drosophila melanogaster testis stem cell niche. Two
distinct kinds of stem cells, germline and cyst, cluster around a small group of somatic cells
called the hub. Distance away from the hub ultimately leads to differentiation. Borrowed from de
Matunis et al., 2012. [44]

Which populations of regular stem cells express ABC transporters? Most of the evidence
comes from vertebrate stem cell populations. The three ABC transporters most notorious for
cancer multidrug resistance, ABCB1, ABCC1, and ABCG2 [45], are also expressed within some
normal hematopoietic stem cell populations [46]. It is thought that these ABC transporters
protect hematopoietic progenitor and stem cells from potentially harmful xenobiotics. ABCB1 is
expressed in human CD34+ stem cells [47]. ABCG2 is highly expressed in most (if not all)
hematopoietic stem cells, including 34+/38- and 34+/KDR+ populations, but expression is largely
lost as these cells mature [48]. Likewise, ABCC1 is expressed at higher levels in hematopoietic
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stem cells than in mature blood cells [49]. Other, less notorious ABC transporters are also
expressed in human 34+/38- hematopoietic stem cells, including several members of subfamilies
ABCA, ABCB, and ABCC [46]. Interestingly, Abcg2 mRNA has been shown to be expressed
within side population cells of both murine embryonic stem cells and skeletal muscle, as well as
its ortholog in rhesus monkey bone marrow, indicating that ABC transporter expression may be a
highly conserved feature of certain stem cell populations [50].
Even though the majority of the evidence for ABC transporter expression in regular stem
cells is specific to hematopoietic stem cells, there is evidence of ABC transporter expression in
non-hematopoietic stem cell populations as well. As mentioned above, ABCG2 is thought to be
expressed in both murine embryonic stem cells and skeletal muscle. Moreover, Tang et al.
characterized the expression profiles of several non-hematopoietic stem cell types, including
adipose-derived human mesenchymal stem cells and human embryonic stem cells (HUES1,
HES2, and HES3), and while they found the overall expression levels of ABC transporters to be
lower in non-hematopoietic compared to hematopoietic stem cells, they did find similar
expression profiles in these other stem cell types, as well as specific transporters unique to nonhematopoietic stem cells [51]. This suggests that stem cells depend not on any single ABC
transporter, but on collections of transporters unique to their cellular identity, resulting in a kind
of redundancy thought to both protect stem cell integrity and contribute to the difficulty of
combating cancer multidrug resistance [51]. Unfortunately, it remains unclear whether many
populations of tissue-specific adult stem cells express ABC transporters, and there have been few
definitive studies on the matter. However, using lineage tracing experiments, Fatima et al. were
able to show that ABCG2 is expressed not only within murine blood stem cells (as is already
widely known), but also within stem cells of the murine small intestine and testis [52]. ABCG2
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has also been shown to be highly expressed within human neural stem and progenitor cells [53].
Future studies will, in all likelihood, identify ABC transporters expressed in even more adult
stem cell populations.
Comparatively less is known about the expression of ABC transporters within
invertebrate stem cell populations. While it has yet to be shown in the literature whether ABC
transporters are active within D. melanogaster testis stem cells, there are a number of reasons to
believe it might be so. First, ABC transporters are found across all three domains of life, from
bacteria to mammals, including a family of 56 proteins encoded in the D. melanogaster genome
(Table 1). Second, there is a growing body of evidence that suggests ABC transporter expression
is a general stem cell trait, shared by both cancer and normal stem cells alike [34, 35], and it
would make evolutionary sense for stem cells of the germline to have a defensive mechanism
such as ABC transporters to protect against cytotoxins. Third, previous research has
demonstrated that D. melanogaster insecticide resistance has coincided with the upregulation of
genes coding for several ABC transporters, and that knockdown of these genes was able to
increase drug susceptibility [54-56]. Using the 91-R strain of D. melanogaster, which is highly
resistant to the insecticide 4,4’-dichlorodiphenyltrichloroethane (DDT), Gellatly et al. showed
that RNAi knockdown of three ABC transporters (Mdr50, Mdr65, and Mrp1) led to decreased
resistance, reducing LT50 values by 13%, 12%, and 15% respectively [54]. Similarly, Kim et al.
induced tolerance to the insecticide Ivermectin in Canton S (wild type) flies and showed that
such tolerance both correlated with the transcriptional upregulation of three ABC transporters
(Mrp1, CG1824, and CG3327) and was reduced following RNAi knockdown of these
transporters. Finally, Denecke et al. used CRISPR-Cas9 knockouts to investigate the contribution
of Mdr49, Mdr50, and Mdr65 in resistance to a variety of insecticides, with knockout mutants
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showing increased susceptibility to 1, 3, and 5 insecticides, respectively [56]. Interestingly, they
also found that treatment with verapamil (an ABC transporter-inhibitor) was able to inhibit
resistance only in flies with at least one function copy of Mdr65, further implicating the
transporter’s role in causing resistance.
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Table 1.1: A list of the 56 ABC Transporters encoded in the Drosophila melanogaster genome.

FAMILY
ABC-A

GENE

HUMAN ORTHOLOGUE*

ABCA
CG1494
CG1801
CG6052
CG8908
CG31213
CG34120
CG42816
CG43672
Eato

ABCA3

ABCA3

ABCA12

ABC-B
CG10226
Mdr49
Mdr50
Mdr65
ABCB7
CG1824
CG3156
Hmt-1

ABCB4/ABCB11
ABCB1
ABCB4
ABCB7
ABCB8
ABCB10
ABCB6

ABC-C
CG4562
CG5789
CG7627
CG7806
CG9270
CG10505
CG11898
CG31792
CG31793
l(2)03659
MRP
Mrp4
rdog
Sur

ABCC4
ABCC4
ABCC10
ABCC4
ABCC4
ABCC4
ABCC4
ABCC4
ABCC4
ABCC3
ABCC4
ABCC4
ABCC9

ABCD
Pmp70

ABCD2
ABCD3

pix

ABCE1

ABC-D

ABC-E

Table 1.1, (Continued)

FAMILY
ABC-A
ABC-D

CG11898
CG31792
CG31793
l(2)03659
MRP
Mrp4
rdog
GENE
Sur

ABCC4
ABCC4
ABCC4
ABCC4
ABCC3
ABCC4
ABCC4
HUMAN ORTHOLOGUE*
ABCC9
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ABCA
ABCA3
ABCD
ABCD2
CG1494
Pmp70
ABCD3
CG1801
ABC-E
CG6052
ABCA3
pix
ABCE1
CG8908
ABC-F
CG31213
CG1703
ABCF1
CG34120
ABCA12
CG9281
ABCF2
CG42816
CG9330
ABCF3
CG43672
ABC-G
Eato
Atet
ABCG4
ABC-B
bw
CG10226
CG3164
Mdr49
ABCB4/ABCB11
CG4822
Mdr50
ABCB1
CG5853
ABCG1
Mdr65
ABCB4
CG9663
ABCB7
ABCB7
CG9664
CG1824
ABCB8
CG11069
ABCG5
CG3156
ABCB10
CG17646
Hmt-1
ABCB6
CG31121
ABC-C
CG31689
CG4562
ABCC4
CG32091
CG5789
E23
CG7627
ABCC4
st
CG7806
ABCC10
w
ABCG2
CG9270
ABCC4
ABC-H
CG10505
ABCC4
CG11147
CG11898
ABCC4
CG33970
CG31792
ABCC4
snu
CG31793
ABCC4
l(2)03659
ABCC4
Note. *Only top human orthologuesMRP
with a FlyBase protein alignment
ABCC3score of 8 out of 15 or
higher were included (corresponding to hits from at least 8 different tools or algorithms used by
Mrp4
ABCC4
FlyBase to determine orthology). Multiple orthologues were listed if they tied for top FlyBase
rdog
ABCC4
scores.
Sur
ABCC9
ABC-D
ABCD
ABCD2
Pmp70
ABCD3
ABC-E
pix
ABCE1
ABC-F
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While evidence supporting the role ABC transporters play in insecticide resistance is
mounting, the only direct evidence of invertebrate stem cell drug resistance to date (to the best of
my knowledge) comes from Dayton et al. [57]. In their BioRxiv preprint, they provided the first
evidence of ABC transporter expression within the intestinal stem cells (ISC) and enteroblast
(EB) progenitors of the D. melanogaster midgut. By feeding flies two cytotoxic drugs
(bortezomib and actinomycin D), dissecting their intestines, and evaluating cell response, they
showed that ISC and EB exhibit increased drug tolerance relative to mature enterocytes. Then,
by feeding flies fluorescent dyes and using RNAi to knockdown 55 of the 56 ABC transporters
in the D. melanogaster genome, they showed that ISC and EB have elevated efflux ability
conferred by seven ABC transporters (CG1494, CG1819, Mdr50, ABCB7, MRP, CG32091, and
CG5853). Next, they used enhancer trap lines to characterize the expression patterns of ABC
transporters in ISCs and EBs relative to mature enterocytes, and found that two of the seven
previously identified ABC transporters, ABCB7 and CG32091, were specific to ISC and EB cell
populations. Finally, they found that RNAi knockdown of these two ABC transporters was
sufficient to restore drug susceptibility to ISCs and EBs.
All of this evidence taken together led to the question of whether ABC transporters play a
role in drug efflux and resistance in D. melanogaster testis stem cells. Here, I present evidence of
cytotoxic drug efflux in the germline stem cells of the D. melanogaster testis. This was
accomplished by feeding doxorubicin to wild type flies for two days and measuring fluorescence
levels using confocal microscopy. Then, using enhancer trap lines, I also present ABC
transporter expression evidence in both the germline and cyst lineages of the testis. Finally,
through RNAi knockdown of several ABC transporters, I present evidence of their contribution
to germline stem cell drug efflux. I also report unexpected phenotypes in the male germline
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resulting from the knockdown of two ABC transporters, CG32901 and CG3164. This work lays
the foundation for future studies involving ABC transporters in the D. melanogaster testis stem
cell niche.

15

CHAPTER II
GENERAL METHODS
Drosophila melanogaster Fly Strains
The Canton S (wild type), Nanos-Gal4, and UAS-GFP fly lines were obtained from Dr.
Stephen DiNardo, and the c587-Gal4 line from Dr. Erica Matunis. All transgenic fly lines listed
in Tables 2 and 3 were obtained from the Bloomington Drosophila Stock Centers (BDSC). All of
the RNAi transgenic lines were created through the joint efforts of the Vienna Drosophila RNAi
Center, the National Institute of Genetics, and the Drosophila Transgenic RNAi Project (TRiP) at
Harvard Medical School [58]. The lines were validated by the RNAi Stock Validation and
Phenotypes Project [58]. All stocks were grown at room temperature and fed on standard fly
medium. For all fly crosses, resulting F1 progeny were incubated at 29° C for approximately one
week in order to induce Gal4 expression prior to any further experimental treatment (drugfeeding, dissection and immunofluorescence staining, etc.).
Immunofluorescence Staining
Testis samples were dissected in Drosophila Ringer’s solution, then incubated in 0.5 mL
of fixative for 20 minutes at room temperature. Fixative solution is 4% formaldehyde and 0.02%
Triton X-100 diluted in Buffer B (75 mM KCl, 25 mM NaCl, 3.3 mM MgCl2, 16.7 mM KPO4);
0.5 mL applied per sample. Following fixation, samples were rinsed twice with PBTx (1X PBS,
0.1% Triton X-100), washed with PBTx, then incubated overnight with 0.5 mL blocking solution
(4% normal donkey serum in PBTx + 0.01% Na Azide) at 4°C. The next day, primary antibodies
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diluted in blocking solution were applied to samples and incubated overnight at 4°C. Fluorescent
antibodies were used to visualize the testis niche. Proteins that accumulate in distinct cell
populations within the testis niche were bound by primary antibodies, which themselves were
bound by secondary antibodies containing fluorophores (i.e. fluorescent compounds that can be
visualized upon light excitation). After removing primary antibodies, samples were washed in
PBTx overnight at 4°C. Secondary antibodies diluted in blocking solution were applied the next
day and incubated overnight at 4°C. Following secondary antibodies, samples were rinsed in
PBTx, incubated with Hoechst nuclear stain (if applicable), and washed overnight at 4°C.
Finally, samples were soaked in a 50% Ringers/50% glycerol solution for at least 30 minutes,
mounted on microscope slides, and imaged using a Zeiss 700 confocal microscope. A threedimensional image of the testis niche was recreated by compiling Z-stacks of 0.5 μm intervals.
All image analysis was done in ImageJ.
The hub, germline cells, and cyst lineage cells were stained using mouse anti-fasciclin 3
antibody (Developmental Studies Hybridoma Bank, 1:50), rabbit or goat anti-vasa antibody
(Santa Cruz, 1:300), and guinea pig anti-traffic jam (TJ) antibody (1:10,000), respectively [59].
Rabbit anti-GFP antibody (Invitrogen, 1:1000) was used to enhance GFP detection in
experiments involving the UAS-GFP reporter line, and rabbit anti-Cleaved Caspace-3 antibody
(Asp175) (Cell Signaling Technology, 1:400) was used to detect apoptosis. All secondary
antibodies were raised in donkey (Jackson ImmunoResearch, 1:400). D. melanogaster testis stem
cells are identified by their proximity to the hub, and therefore do not require stem-cell specific
markers. Hoechst 33342 (Invitrogen; 350 nm excitation maximum and 461 nm emission
maximum), a fluorescent dye that binds to AT-rich regions of DNA, was used at 1 μg/mL.
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Enhancer Traps
To investigate the expression patterns of select ABC transporters, the upstream activating
sequence (UAS)-GFP reporter line was used. To verify its utility, UAS-GFP flies were first
crossed to the driver lines Nanos-Gal4 and c587-Gal4, which drive Gal4 expression in the
germline and cyst lineage, respectively. Following verification, UAS-GFP virgin females were
crossed to males of each of the Gal4 enhancer trap lines from the BDSC (Table 2). Each of these
enhancer trap lines have Gal4 insertions near the gene-of-interest, possibly bringing Gal4
expression under the control of the gene-of-interest’s regulatory sequences. Thus, an ABC
transporter-Gal4 enhancer trap x UAS-GFP cross may result in the expression of GFP within
cells where Gal4 is expressed and able to bind UAS, and therefore recapitulate endogenous ABC
transporter expression. The F1 progeny from each of these crosses were incubated at 29° C for
approximately one week prior to dissection, immunofluorescence staining, and imaging.

Table 2.1: Transgenic Drosophila melanogaster lines used for enhancer trap crosses.
FAMILY
ABC-B type
ABC-C type
ABC-C type
ABC-D type
ABC-G type
ABC-G type
ABC-G type
ABC-G type
ABC-H type

CG#
3879
6214
5772
2316
3164
4822
32091
3327
11147

SYNONYM
Mdr49
MRP
Sur
Abcd1
N/A
N/A
N/A
E23
N/A

STOCK #
24312
77697
25638
78384
76211
77564
29892
25636
25548

LINE TYPE
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap
Gal 4 Enhancer Trap

VENDOR
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC

Quantifying Efflux in Drosophila melanogaster
Germline Stem Cells
To investigate potential drug efflux in the germline stem cells, Canton S flies were fed
food containing the naturally fluorescent chemotherapeutic, doxorubicin (Thermo Fisher
Scientific; 470 nm excitation maximum and 585 nm emission maximum). Doxorubicin is an
intercalating agent that interferes with DNA replication by inhibition of topoisomerase II [60]. It
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is also known to induce cell death via the generation of reactive oxygen species (ROS) [61, 62].
100 μL of 1 mM doxorubicin were added to fresh vials of perforated fly food and allowed to
soak overnight. Flies were added the following day and allowed to feed for two days. Flies fed
on food containing dimethyl sulfoxide (DMSO) served as a negative control. Following feeding,
testes were dissected in Drosophila Ringer’s solution, fixed, and stained using
immunofluorescence as previously described.
Image Analysis and Statistics
All image analysis was done in ImageJ. Differential efflux activity was measured by
comparing the fluorescence pixel intensity of doxorubicin in stem cell populations vs.
differentiating cell populations (i.e. germline stem cells vs. 4- and 8-cell spermatogonia). Rules
for data analysis were as follows: (1) a minimum of three of each cell type was used per testis; if
three of each cell type could not be identified, then that testis was not used. (2) All pixel intensity
measurements were taken with a circular area 2.0 μm in diameter. (3) Pixel intensity
measurements were taken from the brightest part of each cell (with respect to the x, y, and z
planes) clearly within the bounds of the cell nucleus. Differences in mean fluorescence pixel
intensity quantifications between germline stem cells and spermatogonia were tested for
statistical significance using a two-tailed Paired t-Test in Excel. To do this, intensity
measurements for both germline stem cells and spermatogonia were averaged within each testis,
and sample size was determined by the number of testes analyzed. Thus, the Paired t-Test
compared the mean germline stem cell intensity measurement with the mean spermatogonia
intensity measurement within each testis. Statistical significance was further verified using a
pairwise analysis involving nine independent Paired t-Tests in Excel, comparing the first,
second, and third germline stem cell of each testis with the first, second, and third differentiating
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spermatogonia within that same testis. Because the minimum number of testes for any of these
doxorubicin efflux experiments was twenty (n = 20), this resulted in a minimum of 180 cell-tocell pairwise comparisons.
Ribonucleic Acid Interference or Knockout of
ATP-Binding Cassette Transporters
For germline RNAi experiments, the Nanos-Gal4 VP16 driver line was used [63]. This
driver has expression of the Gal4 protein under control of the nos promoter, which is active in
both the male and female D. melanogaster germline. Nanos-Gal4 virgin females were crossed
with males of each of the upstream activating sequence (UAS)-RNAi lines from the BDSC
(Table 2.2), with the exception of stock #58885, which has a loss-of-function genomic mutation
in ABCA and thus required no cross. These RNAi lines were designed to express a doublestranded RNA hairpin loop when UAS binds Gal4, ultimately degrading the mRNA transcript of
interest. Thus, a Nanos-Gal4 x UAS-RNAi cross results in the expression of dsRNA for RNAi
only within Nanos-expressing cells (e.g. germline stem cells and progenitors). The F1 progeny
from each of these Nanos-Gal4 x UAS-RNAi crosses were incubated at 29° C for approximately
one week prior to doxorubicin feeding and analysis (as previously described). The c587-Gal4
driver line was used to investigate RNA interference of CG32091 and CG3164 in the cyst
lineage. To investigate RNA interference of CG32091 and CG3164 in the female germline,
ovaries from progeny of both Nanos-Gal4 x UAS-RNAi crosses were dissected, stained using
immunofluorescence, and imaged in the same manner as the testes. Nanos-Gal4 male and female
flies served as controls for both apoptosis and ovary RNAi experiments.
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Table 2.2: Transgenic Drosophila melanogaster lines used for RNAi knockdown crosses.
FAMILY
ABC-A type
ABC-B type
ABC-C type
ABC-C type
ABC-G type
ABC-G type
ABC-G type
ABC-G type
ABC-H type

CG#
1718
3879
6214
5772
3164
4822
32091
3327
11147

SYNONYM
ABCA
Mdr49
MRP
Sur
N/A
N/A
N/A
E23
N/A

STOCK #
58885
32405
38316
67246
57478
62475
57783
57782
57741

LINE TYPE
Mutant KO
UAS-RNAi
UAS-RNAi
UAS-RNAi
UAS-RNAi
UAS-RNAi
UAS-RNAi
UAS-RNAi
UAS-RNAi

VENDOR
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
BDSC
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CHAPTER III
RESULTS
Investigating Drug Efflux in Germline Stem Cells
Drug efflux via ABC transporters is a hallmark of resistant cancer cells and stem cells
alike. In order to investigate drug efflux in D. melanogaster testis germline stem cells (GSCs),
the drug efflux ability of both GSCs and their differentiating daughter cells (spermatogonia)
were compared. During spermatogenesis, GSCs undergo asymmetric cell division resulting in
two daughter cells, one GSC that self-renews to maintain the stem cell state, and a gonialblast
that exits the niche [37, 44, 64]. Differentiating gonialblasts are enclosed by somatic cyst cells
and undergo four rounds of transit-amplifying spermatogonial divisions before ultimately giving
rise to sperm-producing spermatocytes (see Figure 1.3). Because differentiating germline cells
lose their stem cell characteristics as they move away from the niche, I hypothesized that any
cytotoxic drug efflux ability of the GSCs would be reduced or lost during differentiation. To test
this, wild type (Canton S) flies were fed for two days on food soaked in 1 mM doxorubicin.
Doxorubicin is a common chemotherapeutic used to treat cancer. It is an intercalating agent that
interferes with DNA replication by inhibition of topoisomerase II [60], and is also known to
induce cell death via the generation of reactive oxygen species (ROS) [61, 62]. This drug was
chosen for its natural fluorescence (470 nm excitation maximum, 585 nm emission maximum),
as it can be readily detected using confocal microscopy. DMSO-fed flies served as a negative
control (Figure 3.1 F). Following feeding, fly testes were dissected and imaged using
immunofluorescence confocal microscopy. As seen in Figure 3.1 E, ingested doxorubicin clearly
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reaches the testis. The pixel intensity of the doxorubicin stain was then measured using ImageJ in
both GSCs and differentiating spermatogonia (both 4- and 8-cell spermatogonia were measured),
and the mean GSC pixel intensity value was compared to the mean spermatogonia pixel intensity
value within each testis. After analyzing twenty-three testes (n=23), GSCs were found to have,
on average, lower doxorubicin pixel intensity measurements than differentiating
spermatogonia (P = 4.4 x 10-7; Figure 3.1 A). The statistical significance of this finding was
further verified using a pairwise analysis involving nine independent t-Tests (for each: P < 0.05;
see methodology for details). This result supports the hypothesis that GSCs have increased
cytotoxic efflux ability relative to their differentiating daughter cells. While this difference in
doxorubicin accumulation seems to be modest, in some cases the intensity difference can be
clearly visualized (Figure 3.1 B). To measure the doxorubicin stain in each cell, both the x- and
y-planes were varied, as well as the z-plane (Figure 3.1 C-D), in an attempt to locate the brightest
part of each cell (i.e., the area of highest doxorubicin accumulation). As an additional negative
control, pixel intensity was also measured in the channel used to visualize the Vasa germline
stain. As expected, this did not result in any significant difference between the GSCs and
spermatogonia (Figure 3.1 G-H).
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Figure 3.1: Quantifying cytotoxic drug efflux in GSCs and differentiating spermatogonia.
(A) Bar graph representing the mean pixel intensity of the doxorubicin stain for both GSCs and
spermatogonia. Three of each cell type was measured per testis, and sample size (n) was
determined by the number of testes analyzed. Error bars represent standard error of the mean.
Statistical significance was determined using a two-tailed Paired t-Test in Excel. (B) Maximum
intensity projection showing reduced doxorubicin accumulation in GSCs compared to
differentiating spermatogonia. White and red arrowheads point to GSCs and spermatogonia,
respectively. (C-D) Pixel intensity of the doxorubicin stain was measured using a circular area
2.0 μm in diameter and by varying the x-, y-, and z-planes. Here the intensity measurements can
be seen to increase between z=4 and z=6, representing a 1 μm movement. (E) Representative
testis from a wild type (Canton S) fly fed 1mM Doxorubicin for two days. (F) Representative
negative control testis from a wild type fly fed DMSO for two days showing background staining
in the doxorubicin channel. (G) Bar graph representing the mean pixel intensity of the Vasa
channel showing no significant difference between GSCs and spermatogonia. (H) Example of
measuring pixel intensity in the Vasa channel.
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Selection of ATP-Binding Cassette Transporter
Gene Candidates
Following the observation that GSCs exhibit cytotoxic drug efflux, the next aim was to
determine whether such efflux was due to ABC transporter activity. In order to identify potential
gene candidates from the 56 ABC transporters encoded in the D. melanogaster genome, RNAseq and microarray expression data from four separate studies were consulted [65-68]. Gan et al.
analyzed the mRNA profiles of both wild type and bag of marbles (bam) mutant testes (which
are enriched with undifferentiated stem-like cells) in order to investigate differential gene
expression [65]. This data allows for the identification of genes with potential significance to the
testis stem cell populations. Similarly, Terry et al. carried out microarray analyses in testes
genetically manipulated to be enriched for both cyst stem cell and GSC populations [66]. In
another, more recent approach, Shi et al. analyzed the gene expression profiles of the male
Drosophila germline at several distinct stages of spermatogenesis, including GSCs, gonialblasts,
the two-, four-, eight-, and sixteen-cell transit amplifying stages of spermatogonia, and early and
late spermatocytes [67]. Finally, Vedelek et al. analyzed the transcriptomes of distinct regions of
the testis, including the apical, middle, and basal regions, allowing for the identification of genes
upregulated in the apical region where the stem cell niche is located [68]. By cross-referencing
data from these studies with genes previously implicated in D. melanogaster drug resistance
(Gellatly et al., Kim et al., and Dayton et al., discussed above) [54-57], 10 ABC transporter
candidates were identified (Table 3.1).
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Table 3.1: Selection of ABC transporter gene candidates. Genes selected through reported
mRNA transcript evidence and drug resistance for enhancer trap, RNA interference, and/or
knockout experiments.
FAMILY
ABC-A type
ABC-B type
ABC-C type
ABC-C type
ABC-D type
ABC-G type
ABC-G type
ABC-G type
ABC-G type
ABC-H type

CG#
1718
3879
6214
5772
2316
3164
4822
32091
3327
11147

SYNONYM
ABCA
Mdr49
MRP
Sur
Abcd1
N/A
N/A
N/A
E23
N/A

mRNA EXPRESSION
[65, 67, 68]
[65, 67]
[68]
[65, 67]
[65, 68]
[65, 67]
[65, 66, 67]
[65]
[65, 67]
[65, 67]

DRUG RESISTANCE
[56]
[54, 55, 57]

[57]
[55]

ATP-Binding Cassette Transporter Expression in Cyst
and Germline Stem Cells
While a primary objective of this study was to determine whether or not ABC transporter
activity was behind GSC cytotoxic drug efflux, an even more fundamental question was whether
or not ABC transporters are expressed in either of the D. melanogaster testis stem cell
populations. To the best of my knowledge, no one has investigated ABC transporter expression
patterns in either cyst stem cells or GSCs. To do this, enhancer trap lines were acquired for 9 of
the 10 ABC transporter gene candidates identified (see Table 2.1). Each of these lines have Gal4
insertions near the gene of interest and may have Gal4 expression under the control of ABC
transporter regulator sequences. Thus, by crossing each of these enhancer trap lines to a UASGFP reporter line, it is possible to recapitulate endogenous ABC transporter expression. First, the
integrity of the UAS-GFP reporter line was tested by crossing it to two separate Gal4 driver
lines: Nanos-Gal4, which drives Gal4 expression in the germline, and c587-Gal4, which drives
Gal4 expression in the cyst lineage (Figure 3.2). As expected, this resulted in GFP staining
patterns consistent with cells positive for Vasa, a germline-specific marker (Figure 3.2 A), and
cells positive for Tj, a marker of early cyst cells (Figure 3.2 B). Next, the UAS-GFP reporter line
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was crossed to each of the ABC transporter enhancer trap lines, and the GFP expression patterns
of the F1 testes were analyzed (Figure 3.3 A-I). The results of these enhancer trap experiments
are summarized in Table 3.2. In general, GFP expression fell into four categories: cyst stem cells
and somatic cyst cells only (ABCD); somatic cyst cells only (CG11147); cyst stem cells, somatic
cyst cells, and spermatogonia, but not within GSCs (CG3164); and all four cell types, including
cyst stem cells, somatic cyst cells, GSCs, and spermatogonia (CG4822, CG32091, E23, Mdr49,
MRP, SUR).

Figure 3.2: Positive controls for enhancer trap experiments. (A) Representative testis from
Nanos-Gal4 x UAS-GFP cross showing GFP expression in a pattern consistent with the Vasa
germline stain. (B) Representative testis from c587-Gal4 x UAS-GFP cross showing GFP
expression in a pattern consistent with the Tj cyst lineage stain. All stains (Vasa, GFP, and Tj)
shown in grey. Scale bars are 20 μm. Stem cell hubs marked by asterisks (*).
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Figure 3.3: ABC transporter expression patterns in the Drosophila melanogaster testis niche.
(A-I) Representative testes from each Gal4-ABC Transporter x UAS-GFP crosses. White and red
arrowheads point to GSCs and spermatogonia or spermatocytes, respectively, while white and
red arrows point to cyst stem cells and cyst cells, respectively. GSCs were identified by their
adjacency to the hub, and cyst stem cells were identified as such if within two GSCs from the
hub. All stains (Vasa, GFP, and Tj) shown in grey. Scale bars are 20 μm. Stem cell hubs marked
by asterisks (*).

Table 3.2: Summary of gene expression patterns in the Drosophila melanogaster testis niche
from enhancer trap experiments.
GENE
ABCD
CG3164
CG4822
CG11147
CG32091
E23
Mdr49
MRP
SUR

GSC

Germ

X

CySC
X
X
X

X
X
X
X
X

X
X
X
X
X

X
X
X
X
X

X
X

CYST
X
X
X
X
X
X
X
X
X

Note. *GSC and CySC stand for Germline Stem Cell and Cyst Stem Cell, respectively. Germ
refers to both Spermatogonia and Spermatocytes. Cyst refers to Late-stage Cyst Cells.

These results seem to support the hypothesis that ABC transporters are expressed in D.
melanogaster testis stem cells and their progenitors. However, a high degree of background
staining may call into question the validity of these results. While negative controls involving
only secondary antibodies did not reveal concerning levels of background staining in the stem
cell niche (Figure 3.4 A-B), the results do seem to be confounded by the use of an anti-GFP
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primary antibody (Figure 3.4 C-D). Anticipating that the native GFP expression driven by the
Gal4-UAS system in these enhancer trap experiments might be difficult to detect, an additional
anti-GFP antibody was used and tagged with a fluorescent secondary antibody, with the intention
of enhancing the native GFP expression. This indicated that a portion of the experimental GFP
staining appears to be due not to GFP driven by the Gal4-UAS system, but rather to the nonspecific background staining of the anti-GFP antibody, especially in regions further away from
the stem cell niche (i.e., the region of the spermatocytes and transit-amplifying spermatogonia).
In order to differentiate between true experimental GFP staining and this unwanted background,
repeat experiments should be performed without the anti-GFP antibody. However, there are
aspects of the experimental GFP staining that cannot be explained by background alone. These
include staining in the area of the stem cell niche, staining only in the cyst lineage, such as in the
case of CG11147, and the strong, clean staining observed in the case of MRP, which looks the
most like the Nanos-GFP and c587-GFP positive controls. Additionally, these results could be
further validated using other methods such as in situ hybridization or RT-PCR.
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Figure 3.4: Negative controls for enhancer trap experiments. All testis samples from WT Canton
S flies. (A-B) Representative testes treated with only secondary antibodies. (C-D) Representative
testes treated with secondary antibodies, as well as Hoechst, anti-GFP, and anti-Fas3. Scale bars
are 20 μm. Stem cell hubs (if identifiable) marked by asterisks (*).

Ribonucleic Acid Interference in
Germline Stem Cells
In order to determine whether ABC transporter activity was behind GSC cytotoxic drug
efflux, RNA interference (RNAi) lines were acquired for 8 of the 10 ABC transporter gene
candidates identified, and a true mutant knockout (KO) line was obtained for ABCA (see Table
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2.2). Each of these RNAi lines were crossed to a Nanos-Gal4 driver line, resulting in the
expression of a double-stranded RNA hairpin loop and ultimately the degradation of the ABC
transporter mRNA transcript within Nanos-expressing cells (i.e., GSCs and their progenitors).
Surprisingly, germline RNAi knockdown (KD) of two of these ABC transporters resulted in
extremely abnormal phenotypes in the testis stem cell niche (discussed later). To investigate
whether the other ABC transporters are required in GSC cytotoxic drug efflux, F1 progeny from
each of the RNAi crosses were fed doxorubicin before their testes were dissected, imaged, and
analyzed as previously described. If an ABC transporter is required in GSC drug efflux, then loss
of that transporter should result in an increased accumulation of doxorubicin in the GSCs, and
potentially reduce the difference in doxorubicin accumulation between the GSCs and
spermatogonia. The results of these KD or KO experiments implicated six ABC transporters
(ABCA, CG4822, CG11147, Mdr49, MRP, and E23) in GSC drug efflux. The loss of each of
these proteins resulted in no significant difference in the mean doxorubicin pixel intensity
between GSCs and spermatogonia. The only genotype that was found to maintain a lower
doxorubicin accumulation in the GSCs relative to spermatogonia was the SUR KD, suggesting
that the SUR protein does not function in GSC drug efflux. These results suggest a high level
both of redundancy in export function and overlap in efflux substrate specificity. Experiments
involving other cytotoxic drugs, double or triple RNAi knockdowns, dominant negative mutants
(which might be several members of the fly ABC-B subfamily), and treatment with ABC
inhibitors such as verapamil could help to further illuminate the role these proteins are playing in
GSC cytotoxic efflux.
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Figure 3.5: Germline RNAi KD or KO of select ABC transporters. (A) Representative testis
from wildtype control fly (Nanos-Gal4). (B-H) Representative testes from seven germline RNAi
knockdown crosses. Scale bars are 20 μm. Stem cell hubs marked by asterisks (*).
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Figure 3.6: Effect of germline RNAi KD or KO on cytotoxic drug efflux. Sample size (n) was
determined by the number of testes analyzed per genotype. Error bars represent standard error of
the mean. Statistical significance was determined using a two-tailed Paired t-Test in Excel. The
SUR knockdown (KD) was the only genotype found to have a significant difference between
mean germline stem cell (GSC) pixel intensity and mean spermatogonia pixel intensity.
However, pairwise analysis of the SUR KD resulted in a P < 0.05 for only 3 out of 9 independent
t-Tests.
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Surprisingly, RNAi KD of two ABC transporters, CG32091 and CG3164, resulted in
total or near total loss of the germline cell lineage (Figure 3.7 A-E). Loss of CG32091 also
resulted in dramatic expansion of both Tj-positive cyst cells and Fas3-positive hub cells (Figure
3.7 B-C). It is not clear why loss of these transporters should warrant such extreme phenotypes,
and naturally such observations inspired a number of new lines of inquiry. First, it was not clear
whether germline loss was due to increased levels of cell death or increased differentiation and
movement away from the stem cell niche. To test the hypothesis that loss of CG32091 and
CG3164 was inducing apoptosis in the germline, testes from both KD genotypes were treated
with an anti-Cleaved Caspase-3 antibody. While three instances of cell death were observed in
the Nanos-Gal4 wildtype control testes (n=12), there were no detectable signs of Cleaved
Caspase-3 dependent apoptosis in either KD testes (Figure 3.7 F-H). This suggests that loss of
these transporters does not induce Caspase-3 dependent apoptosis. Next, we wondered if this
phenotype was specific to the germline or whether loss of these transporters might be generally
cell lethal. To test this, both RNAi lines were crossed to the c587-Gal4 driver line to knockdown
CG32091 and CG3164 in the cyst lineage. Interestingly, loss of these transporters in the cyst
lineage resulted in no abnormal phenotype, suggesting a specificity to the germline cell lineage
(Figure 3.7 I-J). Finally, we wondered if loss of these transporters might also impact the female
germline. To investigate this, ovaries from CG32091 and CG3164 KD flies were dissected and
stained using immunofluorescence in the same manner as the testes and imaged with confocal
microscopy. As with the testes, ovaries from Nanos-Gal4 flies served as a control (Figure 3.7 K).
Unlike in the testes, KD of these transporters did not result in any apparent loss or disruption of
the female germline (Figure 3.7 L-M). To confirm that this phenotype is in fact due to loss of
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transporters, future experiments might repeat these loss-of-function experiments using, for
example, CRISPR-Cas9 knockouts instead of RNAi.
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Figure 3.7: Germline RNAi KD of CG32091 and CG3164 results in male-specific germline loss.
(A) Representative testis from wildtype control fly (Nanos-Gal4). (B-C) Germline RNAi of
CG32091 results in loss or disruption of germline and expansion of both the hub and cyst
lineages. (D-E) Germline RNAi of CG3164 results in loss of germline. (F) Wildtype (NanosGal4) testis showing Caspase-3-dependent cell death. (G-H) Germline RNAi of CG32091 and
CG3164 does not result in detectable Caspase-3-dependent cell death. (I-J) Cyst lineage RNAi
knockdown of CG32091 and CG3164 does not result in any abnormal phenotype. (K)
Representative wild type ovary showing germarium and ovarioles. (L-M) Germline RNAi of
CG32091 and CG3164 does not result in loss or disruption of the female germline. Scale bars are
20 μm. Stem cell hubs marked by asterisks (*).
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CHAPTER IV
DISCUSSION
The Utility of Drosophila melanogaster in
Cancer Research
D. melanogaster has a rich history in biological research. Much of our modern
understanding of genetics is heavily indebted to the work of fly geneticists of the 20 st century
through to the present. Not only has Drosophila research unveiled many of the fundamentals of
genetics (including the chromosomal basis of inheritance), but it has also contributed heavily to
biomedical research, including the discovery of many developmental signaling pathways [38,
69]. For example, both the Hedgehog pathway and the Notch pathways were first discovered in
D. melanogaster and were named after their fly mutant phenotypes. Today it is understood that
misregulations of both pathways are contributors to many diseases including cancer [70], and it
is thought that abnormal activation of Sonic Hedgehog signaling (which plays a role in the
regulation of adult stem cell populations) is responsible for the transformation and self-renewal
of cancer stem cells [71]. Additionally, the Hippo signaling pathway was first discovered in D.
melanogaster as a regulator of organ size, and later was recognized as an important tumor
suppressor pathway in humans [72]. In general, the fact that many of the main human signaling
pathways regulating cell growth are conserved in D. melanogaster, including both oncogenic and
tumor suppressor pathways, make the fruit fly a powerful in vivo model for the study of cancer
[42].
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While the cancer stem cell hypothesis was first derived from studies involving mammals,
the D. melanogaster stem cell model systems have the potential to shed new light on many
aspects of cancer stem cells, not the least of which is the question of how cancer stem cells arise
in the first place. Many models for the origin of cancer stem cells have been proposed. Some
posit that cancer stem cells arise directly from normal stem cells, possibly by gaining nicheindependence, while others suggest they arise from transit-amplifying progenitor cells [73].
While probably there will not be one single answer to this question, and the origin of cancer stem
cells will likely vary between different types of cancer, researchers are beginning to answer such
questions with the help of simple model organisms. Using D. melanogaster, Song et al. was able
to show that cancer stem cells of the brain can arise from transit-amplifying progenitors
dedifferentiating back into a stem-like state [74]. These in vivo stem cell model systems also
allow researchers a valuable tool in the effort to find ways to eradicate cancer stem cells without
harming the tissue-specific stem cell populations crucial to an organism’s health and survival.
This is another point well illustrated in the work of Song et al., who showed that cancer stem
cells of the D. melanogaster brain and ovary, because of their dependence on eukaryotic
translation initiation factor 4E (eIF4E), could be eliminated without harming the tissue-specific
stem cell populations residing in those locations [74]. Additionally, many tumor models have
been developed in D. melanogaster, including in areas such as the eye [75], the brain [76], and a
variety of epithelial tumors which have been used to investigate molecular and cellular
mechanisms governing tumorigenesis [77]. Moreover, several stem cell tumor models have also
been developed in D. melanogaster, including an intestinal stem cell model developed by
Markstein et al., used to screen for novel inhibitors of stem cell-derived tumors [78]., as well as
several germline tumor models [65, 79]. The work of Gan et al. was briefly discussed earlier in
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the context of selecting ABC transporter gene candidates, but one point not mentioned was that
their bam mutant testes, which are enriched with undifferentiated stem-like cells, is a stem cell
tumor model of the testis. Interestingly, when comparing the transcriptional profiles of bam and
wild type testes, they reported upregulation of over half the ABC transporters encoded in the D.
melanogaster genome (32/56). Given such a finding, future studies might investigate the role of
ABC transporters in these D. melanogaster tumor models, and especially those derived from
stem cells and/or progenitors.
Evidence of ATP-Binding Cassette Transporter Expression and
Function in the Drosophila melanogaster
Testis Stem Cell Niche
Regarding the current study, the results have potential implications for both cancer and
developmental biology. Rather than being unique to cancer stem cells, there is mounting
evidence that ABC transporter expression is a general stem cell trait, and the current study lends
evidence in favor of that view. Given the significance of ABC transporter activity in both cancer
multidrug resistance and antibiotic resistance (among other biomedical concerns), there is much
interest in targeting ABC transporters therapeutically, as well as growing evidence that such
targeting might prove effective [3, 4, 22-25]. As previously mentioned, D. melanogaster has
already been established as a model organism for large-scale drug screens [78, 80], but the
research proposed here could set the foundation for similar screens using the D. melanogaster
testis niche to identify, for example, small molecule inhibitors for future combinatorial therapies
to make conventional chemotherapies more effective. The establishment of the D. melanogaster
testis niche as a tool for the study of ABC transporters would allow researchers to study these
proteins in vivo, an ability that is especially important for stem cells which are heavily influenced
by signaling from their local microenvironments. Since the D. melanogaster testis niche is one of
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the best understood stem cell niches, it would also be an ideal setting in which to study ABC
transporter gene expression, many aspects of which are not yet well understood, such as how
gene expression is regulated between stem cells and their progeny and whether their expression
is induced by chemotherapeutics (see Appendix B).
The current work has presented evidence not only of ABC transporter expression in the
D. melanogaster testis stem cell niche, including stem cells and progenitors of both stem cell
lineages, (Figure 3.3; Table 3.2) but also evidence of six ABC transporters functioning in GSC
cytotoxic drug efflux, specifically when exposed to doxorubicin (Figure 3.1; Figure 3.6). While
the natural fluorescence of doxorubicin makes useful for quantifying efflux, this drug did not
cause any detectable disruption or stress to the testis architecture, even after longer periods of
exposure at a ten-fold higher concentration (data not shown). Treatment with other drugs
(perhaps Actinomycin D or Bortezomib) causing detectable disruption of the testis architecture
might better illuminate the resistance properties of the germline or cyst stem cells. If such
resistance were found relative to the surrounding tissue, then the resistance properties of ABC
transporters could be further investigated. Expanding to other drugs would also make sense in
the context of ABC transporter substrate specificity. While there is considerable overlap in efflux
substrates, they are not identical. For instance, doxorubicin is a substrate shared by the three
most notorious proteins involved in human multidrug resistance, ABCB1, ABCC1, and ABCG2,
but the ABC inhibitor verapamil is a substrate only of ABCB1 [12]. Experiments with a diverse
range of drugs could lead to insights regarding the substrate specificities of the D. melanogaster
ABC transporter family.
This investigation has focused on just 10 of the ABC transporters encoded in the D.
melanogaster genome, but there is ample evidence to broaden the scope of this research and
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investigate the other 46 as well. And while most of the functional RNAi experiments reported
here focused on the germline, there is no reason not to investigate the role ABC transporters
might play in the cyst lineage as well. After all, results from the GFP enhancer trap experiments
suggest that some ABC transporters, such as ABCD and CG11147, are exclusively expressed in
the cyst lineage and not in the germline (Figure 3.3; Table 3.2). Although there does appear to be
a discrepancy here, because RNAi KD of CG11147 also resulted in decreased GSC cytotoxic
drug efflux (Figure 3.6), a result which should not be possible if CG11147 were only expressed
in the cyst lineage. Further experiments will be needed to address this apparent discrepancy. In
contrast, other results seem to complement each other nicely. RNAi KD of MRP also decreased
GSC cytotoxic drug efflux (Figure 3.6), and this finding is consistent with the results of the
enhancer trap experiments. Of the 10 ABC transporters investigated, MRP had the strongest,
cleanest staining pattern, with compelling expression evidence in both the germline and cyst
lineages (Figure 3.3 H). Given such strong expression evidence, it is possible that MRP is also
playing some functional role in the cyst lineage as well.
An Unexpected Role for CG32091 and CG3164
in the Male Germline
A broader investigation of ABC transporters could also lead to interesting findings not
only in the context of stem cell drug resistance and cancer, but also in development. Clearly, two
of the ABC transporters investigated here, CG32091 and CG3164, are playing some previously
undescribed role in the D. melanogaster testis stem cell niche. Why germline RNAi KD of these
two transporters leads to total (or near total) loss of the germline is an open question. Since
germline KD of CG32091 and CG3164 did not result in any detectable cleaved Caspase-3
(Figure 3.7 F-H), it would seem that loss of these transporters does not induce apoptosis. Perhaps
a Caspase-3 independent cell death program is being activated. If not cell death, then perhaps the
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GSC homeostasis is being biased toward differentiation instead of self-renewal, ultimately
leading to loss of the lineage, or perhaps the self-renewal capabilities of the GSCs are being
compromised altogether. It also seems plausible that loss of these genes is disrupting germline
enclosure by the cyst cells. Further experiments will be needed to discriminate between these
possibilities. In whatever case, it is clear that both these KD phenotypes are specific to the male
germline, as neither cyst lineage KD nor female germline KD resulted in any abnormal
phenotypes (Figure 3.7 I-M). There is a clear difference, however, between the CG32091 KD
phenotype and the CG3164 KD phenotype. While germline RNAi KD of either gene results in
germline loss, only RNAi of CG32091 results in dramatic expansion of both the hub and cyst
lineages (Figure 3.7 B-E). This difference in phenotype might suggest a difference in function as
well, indicating that in each case the germline is being lost for different reasons. Here again,
further experimentation is needed.
Other instances of male germline loss have been reported in the literature. For example,
Shields et al. illustrated that loss of the chickadee gene (which encodes profilin, a protein
necessary for actin-polymerization) results in loss of GSCs, most likely due to defects at the
GSC-hub interface [81]. Similarly, Chen et al. illustrated that gilgamesh, a homologue of casein
kinase 1-γ, was necessary for GSC maintenance, and that loss of gilgamesh dramatically reduced
the number of GSCs in the testis niche [82]. Interestingly, studies in yeast have also implicated
gilgamesh in regulation of membrane transport, but precise details of this have yet to be worked
out [83]. Other studies have illustrated that GSCs are susceptible to high levels of reactive
oxygen species (ROS). ROS disrupt GSC homeostasis by favoring differentiation over selfrenewal, ultimately decreasing GSC number, a phenomenon Tan et al. propose is due to changes
in EGFR signaling [84]. What connection, if any, these studies may have to the extreme
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phenotypes of CG32091 and CG3164 KD described here remains unclear. However,
understanding both the intrinsic and extrinsic vulnerabilities of GSCs may amount to valuable
clues in the effort to understand these new phenotypes.
In searching for possibilities, it may be fruitful to consider the known roles played by
ABC transporters in other tissues, and perhaps especially those not directly relevant to cancer
multidrug resistance. It may be that ABC transporters of the D. melanogaster testis niche
function in hormone uptake. In 2018, Okamoto et al. showed that a membrane transporter, which
they named Ecdysone Importer (Ecl), is responsible for cellular uptake of the steroid hormone
ecdysone [85]. Ecdysone binds to a nuclear receptor to induce transcription of genes involved in
insect molting and metamorphosis [86]. While Ecl is a member of the solute carrier organic ion
(SLCO) superfamily of proteins, previous research demonstrated that the packaging of ecdysone
into secretory vesicles is facilitated by the ABC transporter, Atet [87]. Enticingly, both Atet and
the two ABC transporters identified in the current work, CG32091 and CG3164, are members of
the ABC-G subfamily. This homology might suggest functional similarity as well. Another
member of the ABC-G subfamily, E23, also functions in hormone regulation. Hock et al.
illustrated that E23 can behave as a negative regulator of ecdysone, suppressing ecdysonemediated gene transcription [88]. Taken together, these studies reveal not only that steroid
hormones are clearly substrates of ABC transporters, but also that ABC transporters can play
interesting and varied roles in regulating steroid hormones. Finally, Syed et al. recently found
that ecdysone has a role in regulating gene expression in D. melanogaster neural stem cells [89].
Given the roles other members of the ABC-G subfamily have been found to play in hormone
transport, this recent finding that ecdysone regulates gene expression in neural stem cells, and the
detection of localized ecdysone in the testis [90], it would not be all that surprising to discover
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similar roles related to hormone transport or regulation for CG32091 and CG3164 in the D.
melanogaster testis stem cells.
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APPENDIX A
AN EX VIVO ASSAY TO INVESTIGATE DYE EXCLUSION
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“Side population” cells were first discovered for their ability to exclude membranepermeable dyes through increased efflux [31] , and have since been discovered in a variety of
tissues including the skin, heart, and brain [32]. Cancer stem cells use this elevated efflux ability
to attain chemoresistance, and the same has also been found to be true for many normal stem cell
populations in vertebrates. In their BioRxiv preprint, Dayton et al. [57] have gone on to show
that the phenomenon of dye exclusion also extends to invertebrate stem cells as well, specifically
in the intestinal stem cells and enteroblast progenitors of the D. melanogaster gut. All of this
taken together led to the question of whether such dye exclusion properties would be present in
the stem cells of the D. melanogaster testis as well. To test this idea, D. melanogaster testes were
exposed to a variety of membrane- permeable SYTO dyes. SYTO dyes 17 and 59-64 (Table A.1)
are from the SYTO Red Fluorescent Nucleic Acid Sampler Kit (Thermo Fisher Scientific).

Table A.1: Spectral characteristics of SYTO 17 and SYTO 59–SYTO 64 (Thermo Fisher
Scientific).
DYE

Excitation (nm)

Emission (nm)

SYTO 17

621

634

SYTO 59

622

645

SYTO 60

652

678

SYTO 61

628

645

SYTO 62

652

676

SYTO 63

657

673

SYTO 64

599

619

Because these SYTO dyes were not detectable following feeding, an ex vivo approach
was used. Wild type (Canton S) testes were dissected in Ringer’s and incubated for 2 hours in a 5
μM SYTO dye solution in Schneider’s Drosophila Medium. 7 SYTO dyes were used in total

55
(SYTO 17, 59-64), and testes incubated only in Schneider’s served as a negative control.
Following incubation, testes were fixed and stained using immunofluorescence as previously
described. In theory, ABC transporters would still be functional prior to sample fixation and
capable of efflux.
The staining patterns of each of the SYTO dyes in the D. melanogaster testis niche can
be observed in Figure A.1. Each of the SYTO dyes appear to be excluded, to somewhat varying
degrees, from the nuclei of GSCs and their progenitors. In some cases, most dramatically
illustrated by SYTO 64, it appears that encystment of the transit-amplifying spermatogonia is
playing a role in excluding dye from the germline cells. Within germline nuclei, nucleolus
staining was also present to varying extents, with SYTO 17 and 64 seeming to have the least,
perhaps suggesting that these two dyes are the most susceptible to efflux. This experiment serves
as a proof of concept, illustrating the possibility of studying dye exclusion using the D.
melanogaster testis stem cell niche. This ex vivo approach could naturally be extended to future
experiments with other dyes, drugs, and flies of varying genotypes. Future experiments with
these SYTO dyes might also vary dye concentration and incubation time. A natural follow up to
this experiment would be to investigate the effect of ABC transporter KD or KO on the
phenomenon dye exclusion in the testis niche.
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Figure A.1: Staining patterns of SYTO dyes 17 and 59-64 in the Drosophila melanogaster testis
niche using an ex vivo approach. All testis samples came from wild type (Canton S) flies. Scale
bars are 20 μm. Stem cell hubs marked by asterisks (*).
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APPENDIX B
TRANSCRIPTIONAL UPREGULATION OF ATP-BINDING
CASSETTE TRANSPORTERS FOLLOWING
CYTOTOXIC DRUG EXPOSURE
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Upregulation of ABC transporters upon cytotoxic exposure could be a protective
mechanism that evolved in order to ensure successful gamete production. Understanding how
these genes are activated and regulated within the stem cell niche could lead to important
insights in how they function within the tumor microenvironments. Given that past studies in D.
melanogaster have reported an upregulation of ABC transporter genes coinciding with cytotoxic
drug resistance, we hypothesized that cytotoxic drug exposure will result in a transcriptional
upregulation in the D. melanogaster testis niche.
To investigate differential RNA expression of four ABC transporters (MRP, E23, Mdr49,
and CG32091) in the testis stem cell niche following in vivo drug exposure, wild-type flies
(Canton S) were fed food containing the naturally- fluorescent chemotherapeutic, doxorubicin
(Thermo Fisher Scientific). 100 μL of 1 mM doxorubicin were added to fresh vials of perforated
fly food and allowed to soak overnight. Flies were added the following day and allowed to feed
for three days. Flies fed on food containing dimethyl sulfoxide (DMSO) served as a negative
control. Following feeding, 200 testes (100 experimental, 100 control) were harvested in
Drosophila Ringer’s solution, and testis tips (where the stem cell niche resides) were severed
using sharpened forceps and immediately stored in TRIzol™. Total RNA was extracted using
TRIzol™ Plus RNA Purification Kit (following Invitrogen user guide protocol for tissue
samples). Testis samples were collected in 30-minute intervals before being transferred to 0.5
mL of TRIzol™ Reagent and stored at –20°C. cDNA was synthesized using SuperScript III
reverse transcriptase (Invitrogen 18080-044). For quantitative PCR, a PowerTrack SYBR Green
(ThermoFisher) qPCR assay was utilized with a subsequent melt-curve analysis, following the
manufacturer’s protocols. The melt-curve analysis was used to validate the amplification curves
and verify that the targets of interest were the only sequences being amplified. Samples were run
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on a BioRad CFX384 Touch Real-Time PCR Detection System using the following parameters:
1 cycle at 95°C for 2 minutes followed by 40 cycles with 95°C for 5 seconds and 60°C for 30
seconds, and a final cycle of 95°C for 15 seconds prior to the melt curve. The melt curve ramped
up from 60°C to 92°C in increments of 1.6°C with 1 minute at each temperature. As a positive
control, a reference gene, Zfh-1, which encodes a zinc finger homeodomain protein known to be
expressed in the D. melanogaster testis niche, was included [91].

Table B.1: Primers utilized for qPCR.
Name

Forward

Reverse

MRP

CTTCTACTGGGCGTTCGTGA

GCTCACGTTCAGCTTGTTCC

Product
Length
88 bp

E23

CAGAGCGGTGATGTCGAGTT

CGCCCAGCAGTTACGAGATT

94 bp

MDR49

TGCATCGGAGTAGGACTTCAG

AGTGTCTGCTTTCGTCTACGG

139 bp

CG32091

GCGGGATGTATGTGGGTTTC

CCAAAGAACAGACCGCACAG

126 bp

ZFH1

TGCGGGGTTAATTCGGGAG

GGTCACACTGGTGTTAAAGGG

120 bp

An initial qPCR assay and melt curve analysis was performed using only the ZFh1
positive control (Figure B.1), resulting in Cq values around 32 and melt peaks around 78°C for
both control and experimental samples. A subsequent qPCR assay and melt curve analysis using
all the genes of interest was performed. Results indicated that mRNA transcripts of only one
gene of interest (MRP) were upregulated following drug exposure (Figure B.2), while the others
remained unchanged (Mdr49) or appeared to be downregulated (CG32091, E23). Precise Cq
values and melt peak temperatures for each gene are reported in Tables B.2 and B.3,
respectively. The matching melt peak temperatures in both the experimental and control indicate
that the same target gene was amplified in each sample.

61

Figure B.1: Amplification cycles and melt curve peaks for the Zfh1 control. Two melt peaks at
78°C confirm that the same gene target has been amplified in both the experimental and control.
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Figure B.2: Amplification cycles and melt curve peaks for all four genes of interest and Zfh1
control. Two melt peaks at each distinct temperature confirm that the same gene targets have
been amplified in both the experimental and control.
Table B.2: Cq Values
MRP
E23
MDR49
CG32091
ZFH1

Experimental
24.57
33.11
32.19
32.92
33.74

Control
29.00
29.06
32.48
32.04
32.70

Note. Cq (quantitative cycle) values which correspond inversely to the amount of cDNA (and
thus mRNA) present in sample.

Table B.3: Melt Curve Peaks
MRP
E23
MDR49
CG32091
ZFH1

Experimental
80.5°C
81.0°C
n.a. (approx. 87.0°C)
82.5°C
78.0°C

Control
80.5°C
81.5°C
87.0°C
82.5°C
78.0°C

Note. Melt peaks from melt curve analysis of each qPCR sample. The matching melt peak
temperatures in both the experimental and control indicate that the same target gene was
amplified in each sample.
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Of the genes investigated here, only MRP mRNA was upregulated following doxorubicin
exposure. This suggests that MRP is the only ABC transporter of those studied whose expression
levels in the D. melanogaster testis niche is sensitive to doxorubicin exposure. However, it is
possible that the other three ABC transporters (E23, MDR49, and CG32091), which all appear to
be transcriptionally expressed (Figure B.2), might be sensitive to cytotoxic compounds other
than doxorubicin. This is entirely possible, as ABC transporters are known to vary widely in the
substrates they transport. The results of this study also do not rule out the possibility that
doxorubicin may be a transportable substrate of these three non-upregulated ABC transporters,
as each appears to have a baseline level of expression already established. Although an absolute
qPCR assay would be required to ascertain this level of expression for certain. Replicate
experiments would be required to statistically validate the results of this study. In the future, the
assay utilized here could serve to investigate the expression of other genes in the D.
melanogaster testis niche. It would also be interesting to investigate the mechanism by which
transcriptional regulation occurs (including the apparent doxorubicin-induced upregulation
reported here). In cancer cells, expression of ABC transporters is regulated by a number of
transcription factors, and upregulation can be influenced by components of malignant
transformation such as P53, APC, and the MAPK/ERK pathway [92]. Comparatively less is
known about the transcriptional regulation of ABC transporters in stem cells, and this could be
the subject of interesting future studies.

